BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Preclinical Data On AngioChem Pain Program Published In Journal Of Clinical Investigation


2/18/2014 9:58:18 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MONTREAL--(BUSINESS WIRE)--Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced that its neuropeptide conjugate, ANG2002, a new chemical entity formed by conjugation of the peptides Angiopep-2 (An2) and neurotensin, successfully crosses the BBB to achieve therapeutic concentrations in the brain. Analgesic efficacy was demonstrated at low systemic doses of ANG2002 in rat models of neuropathic, inflammatory, and cancer pain, this efficacy was associated with a good safety profile. Despite its non-opiate mechanism, ANG2002 analgesic efficacy is similar to that of morphine. Furthermore, these results underscore the potential of the company’s technology to develop novel biologic therapeutics that crosses the BBB for CNS-related indications.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

AngioChem
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES